Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR

Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:1-9

Published Date: 22 January 2021

Review

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy

Sigmund AM, Sahasrabudhe KD, Bhatnagar B

Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:7-20

Published Date: 3 November 2020

Original Research

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M

Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5

Published Date: 24 August 2020

Review

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Lai C, Kandahari AM, Ujjani C

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:63-71

Published Date: 9 December 2019

Original Research

Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1

Narimani M, Sharifi M, Jalili A

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:53-61

Published Date: 27 November 2019

Review

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

Carrà G, Cartellà A, Maffeo B, Morotti A

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:45-52

Published Date: 6 November 2019

Original Research

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens

Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43

Published Date: 19 August 2019

Review

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:19-32

Published Date: 27 June 2019

Review

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Schieber M, Ma S

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:9-17

Published Date: 12 March 2019

Review

Strategies for minimal residual disease detection: current perspectives

Andreani G, Cilloni D

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:1-8

Published Date: 12 February 2019

Review

Plasmablastic lymphoma: current perspectives

Lopez A, Abrisqueta P

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:63-70

Published Date: 4 October 2018

Review

Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

Hefazi M, Litzow MR

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:47-61

Published Date: 25 September 2018

Review

Current understanding of the role and regulation of miRNAs in Burkitt lymphoma

Videtta AD, Malagnino V, De Falco G

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:33-45

Published Date: 11 May 2018

Review

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

Blum A, Bazou D, O'Gorman P

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:21-31

Published Date: 20 April 2018

Original Research

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era

Lapuz C, Enjeti AK, O'Brien PC, Capp AL, Holliday EG, Gupta SA

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:13-20

Published Date: 18 April 2018

Erratum

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]

Anagnostou T, Litzow MR

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:11-12

Published Date: 11 April 2018

Review

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives

Anagnostou T, Litzow MR

Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:1-9

Published Date: 22 December 2017

Review

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

Trottier AM, Cerquozzi S, Owen CJ

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:85-93

Published Date: 11 December 2017

Review

Impact of obinutuzumab alone and in combination for follicular lymphoma

Sarraf Yazdy M, Cheson BD

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:73-83

Published Date: 19 October 2017

Review

Complications and management of coagulation disorders in leukemia patients

Lad DP, Jain A, Varma S

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:61-72

Published Date: 18 September 2017

Review

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Bhutani D, Zonder JA

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:53-60

Published Date: 19 July 2017

Review

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

Karantanos T, Politikos I, Boussiotis VA

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:37-52

Published Date: 9 May 2017

Review

Clinical potential of midostaurin in advanced systemic mastocytosis

Chandesris MO, Damaj G, Lortholary O, Hermine O

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:25-35

Published Date: 3 May 2017

Original Research

Uptake of lymphoma-derived exosomes by peripheral blood leukocytes

Ferguson Bennit HR, Gonda A, Oppegard LJ, Chi DP, Khan S, Wall NR

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:9-23

Published Date: 28 February 2017

Review

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

Oncale MB, Maymani H, Nastoupil LJ

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:1-7

Published Date: 16 February 2017

Review

Waldenström macroglobulinemia: biology, genetics, and therapy

Paludo J, Ansell SM

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:49-58

Published Date: 26 July 2016

Review

Managing treatment-related peripheral neuropathy in patients with multiple myeloma

Grammatico S, Cesini L, Petrucci MT

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:37-47

Published Date: 29 June 2016

Review

Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes

Faiman B, Valent J

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:21-35

Published Date: 24 May 2016

Review

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

Vaddi K, Verstovsek S, Kiladjian JJ

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:7-19

Published Date: 12 May 2016

Review

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Madanat YF, Smith MR, Almasan A, Hill BT

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:1-6

Published Date: 15 March 2016

Review

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

Bodiford A, Talbott MS, Reddy NM

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:109-114

Published Date: 11 September 2015